JP5809068B2 - 免疫抑制−関連疾患の治療 - Google Patents
免疫抑制−関連疾患の治療 Download PDFInfo
- Publication number
- JP5809068B2 JP5809068B2 JP2011551250A JP2011551250A JP5809068B2 JP 5809068 B2 JP5809068 B2 JP 5809068B2 JP 2011551250 A JP2011551250 A JP 2011551250A JP 2011551250 A JP2011551250 A JP 2011551250A JP 5809068 B2 JP5809068 B2 JP 5809068B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- blscs
- patient
- cancer
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 35
- 201000010099 disease Diseases 0.000 title claims description 28
- 230000001506 immunosuppresive effect Effects 0.000 title claims description 16
- 206010062016 Immunosuppression Diseases 0.000 title claims description 15
- 238000011282 treatment Methods 0.000 title claims description 14
- 210000004027 cell Anatomy 0.000 claims description 77
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 claims description 45
- 210000000130 stem cell Anatomy 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 11
- 230000002062 proliferating effect Effects 0.000 claims description 11
- 230000001404 mediated effect Effects 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000001565 modulated differential scanning calorimetry Methods 0.000 description 39
- 238000000034 method Methods 0.000 description 31
- 206010028980 Neoplasm Diseases 0.000 description 24
- 201000011510 cancer Diseases 0.000 description 18
- 230000004069 differentiation Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 102000003729 Neprilysin Human genes 0.000 description 10
- 108090000028 Neprilysin Proteins 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 8
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 7
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 6
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 206010018910 Haemolysis Diseases 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 230000008588 hemolysis Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000001778 pluripotent stem cell Anatomy 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 210000003014 totipotent stem cell Anatomy 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 210000001671 embryonic stem cell Anatomy 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 description 3
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 3
- 102100022338 Integrin alpha-M Human genes 0.000 description 3
- 108010004729 Phycoerythrin Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 108010004469 allophycocyanin Proteins 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 208000024908 graft versus host disease Diseases 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 102100021723 Arginase-1 Human genes 0.000 description 2
- 101710129000 Arginase-1 Proteins 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000030944 contact inhibition Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 210000003981 ectoderm Anatomy 0.000 description 2
- 210000001900 endoderm Anatomy 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 230000008629 immune suppression Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000004031 neuronal differentiation Effects 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HOZCHTFDGMSKNK-UHFFFAOYSA-N 6-methylspiro[4.5]dec-9-ene-10-carboxylic acid Chemical compound CC1CCC=C(C(O)=O)C11CCCC1 HOZCHTFDGMSKNK-UHFFFAOYSA-N 0.000 description 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 1
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 1
- 102100022749 Aminopeptidase N Human genes 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 1
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 1
- 101000713575 Homo sapiens Tubulin beta-3 chain Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 102000008763 Neurofilament Proteins Human genes 0.000 description 1
- 108010088373 Neurofilament Proteins Proteins 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 101100450270 Oryzias latipes hcea gene Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101100182935 Penicillium citrinum MSDC gene Proteins 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102100036790 Tubulin beta-3 chain Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000002293 adipogenic effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000001201 calcium accumulation Effects 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000004836 empirical method Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 208000003669 immune deficiency disease Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 238000012760 immunocytochemical staining Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 230000003039 myelosuppressive effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000005044 neurofilament Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 201000000235 ovarian squamous cell carcinoma Diseases 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000617 superantigen Toxicity 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 201000002311 trypanosomiasis Diseases 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Gynecology & Obstetrics (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/391,581 US8563307B2 (en) | 2009-02-24 | 2009-02-24 | Treatment of immunosuppression-related disorders |
| US12/391,581 | 2009-02-24 | ||
| PCT/US2010/024735 WO2010099044A2 (en) | 2009-02-24 | 2010-02-19 | Treatment of immunosuppression-related disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012518646A JP2012518646A (ja) | 2012-08-16 |
| JP2012518646A5 JP2012518646A5 (enExample) | 2012-11-29 |
| JP5809068B2 true JP5809068B2 (ja) | 2015-11-10 |
Family
ID=42631141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011551250A Expired - Fee Related JP5809068B2 (ja) | 2009-02-24 | 2010-02-19 | 免疫抑制−関連疾患の治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8563307B2 (enExample) |
| EP (1) | EP2400971B1 (enExample) |
| JP (1) | JP5809068B2 (enExample) |
| CN (1) | CN102325537B (enExample) |
| ES (1) | ES2582582T3 (enExample) |
| TW (1) | TWI496888B (enExample) |
| WO (1) | WO2010099044A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8563307B2 (en) | 2009-02-24 | 2013-10-22 | James Wang | Treatment of immunosuppression-related disorders |
| US8679474B2 (en) | 2010-08-04 | 2014-03-25 | StemBios Technologies, Inc. | Somatic stem cells |
| US8741642B2 (en) | 2010-10-22 | 2014-06-03 | Virginia Commonwealth University | Methods for producing autologous immune cells resistant to myeloid-derived suppressor cells effects |
| TWI614340B (zh) | 2011-09-28 | 2018-02-11 | 幹細胞生物科技股份有限公司 | 體幹細胞及其製備方法 |
| WO2013176785A1 (en) * | 2012-05-21 | 2013-11-28 | The Trustees Of Columbia University In The City Of New York | Trefoil family factor and uses thereof |
| CN104822827B (zh) | 2012-12-06 | 2020-01-21 | 干细胞生物科技公司 | Lgr5+体干细胞 |
| EP2746769A1 (en) * | 2012-12-21 | 2014-06-25 | Stembios Technologies, Inc. | Method for evaluating effect of action on subject based on stem celldynamics |
| US9212225B1 (en) * | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
| HK1253512A1 (zh) | 2015-05-29 | 2019-06-21 | Amphivena Therapeutics, Inc. | 双特异性cd33和cd3结合蛋白质的使用方法 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2936171B2 (ja) | 1989-09-01 | 1999-08-23 | 東ソー株式会社 | 血清アルブミンの製造方法 |
| US6004807A (en) | 1992-03-30 | 1999-12-21 | Schering Corporation | In vitro generation of human dendritic cells |
| US6916654B1 (en) * | 1992-06-29 | 2005-07-12 | Oklahoma Medical Research Foundation | Universal donor cells |
| EP0972039A1 (en) * | 1997-03-25 | 2000-01-19 | Morphogenesis, Inc. | Universal stem cells |
| WO1999026639A1 (en) | 1997-11-26 | 1999-06-03 | Allegheny University Of The Health Sciences | Methods for mobilizing hematopoietic facilitating cells and hematopoietic stem cells into the peripheral blood |
| AU3456099A (en) | 1998-03-31 | 1999-10-18 | Geron Corporation | Methods and compositions for eliciting an immune response to a telomerase antigen |
| US6080399A (en) | 1998-04-23 | 2000-06-27 | Arch Development Corporation | Vaccine adjuvants for immunotherapy of melanoma |
| JP3553858B2 (ja) | 1999-08-25 | 2004-08-11 | 東洋紡績株式会社 | 血管網類似構造体を有する細胞培養用モジュール |
| US20030161817A1 (en) | 2001-03-28 | 2003-08-28 | Young Henry E. | Pluripotent embryonic-like stem cells, compositions, methods and uses thereof |
| US7575921B2 (en) | 1999-12-30 | 2009-08-18 | Vbi Technologies, L.L.C. | Spore-like cells and uses thereof |
| US20020151050A1 (en) | 2000-10-30 | 2002-10-17 | Vacanti Charles A. | Isolation of spore-like cells from tissues exposed to extreme conditions |
| JP3977136B2 (ja) | 2001-05-22 | 2007-09-19 | キヤノン株式会社 | コイルユニット |
| US7316932B2 (en) | 2001-10-01 | 2008-01-08 | Stemcell Technologies Inc. | Method for separating cells |
| US7736892B2 (en) | 2002-02-25 | 2010-06-15 | Kansas State University Research Foundation | Cultures, products and methods using umbilical cord matrix cells |
| US20070233391A1 (en) | 2002-03-07 | 2007-10-04 | Cambridge University Technical Service Limited (CUTS) | Scd fingerprints |
| AU2003241252A1 (en) | 2002-06-06 | 2003-12-22 | Immunicum Ab | New method and composition for producing a cellular allogeneic vaccine |
| WO2004042023A2 (en) * | 2002-11-01 | 2004-05-21 | Five Prime Therapeutics, Inc. | Stem cell libraries |
| US20060252150A1 (en) * | 2002-11-08 | 2006-11-09 | Linzhao Cheng | Human embryonic stem cell cultures, and compositions and methods for growing same |
| US20050003533A1 (en) | 2003-05-08 | 2005-01-06 | Pawel Kalinski | Mature type-1 polarized dendritic cells with enhanced IL-12 production and methods of serum-free production and use |
| US20090004661A1 (en) | 2003-05-26 | 2009-01-01 | Reliance Life Sciences Pvt Ltd. | Method of growing mesenchymal stem cells from bone marrow |
| ES2265199B1 (es) | 2003-06-12 | 2008-02-01 | Cellerix, S.L. | Celulas madre adultas multipotentes procedentes de condrocitos desdiferenciados y sus aplicaciones. |
| AU2004249812B8 (en) * | 2003-06-25 | 2011-09-15 | Ottawa Hospital Research Institute | Methods and compositions for modulating stem cell growth and differentiation |
| US7622108B2 (en) | 2004-04-23 | 2009-11-24 | Bioe, Inc. | Multi-lineage progenitor cells |
| EP1789540B9 (en) | 2004-09-03 | 2012-02-22 | Moraga Biotechnology Inc. | Non-embryonic totipotent blastomer-like stem cells and methods therefor |
| WO2006070370A2 (en) | 2004-12-29 | 2006-07-06 | Hadasit Medical Research Services & Development Limited | Stem cells culture systems |
| US8846395B2 (en) | 2005-06-01 | 2014-09-30 | Wisconsin Alumni Research Foundation | Generation of mature myelomonocytic cells through expansion and differentiation of pluripotent stem cell-derived lin-CD34+CD43+CD45+progenitors |
| RU2417093C2 (ru) | 2005-06-24 | 2011-04-27 | Дезерт Лейк Текнолоджиз | Очищенный компонент цианобактерий и способ применения |
| WO2007026353A2 (en) | 2005-08-29 | 2007-03-08 | Technion Research & Development Foundation Ltd. | Media for culturing stem cells |
| US20080305079A1 (en) * | 2006-01-06 | 2008-12-11 | Mount Sinai School Of Medicine Of New York University | Myeloid Suppressor Cells, Methods For Preparing Them, and Methods For Using Them For Treating Autoimmunity |
| CA2640087A1 (en) | 2006-01-25 | 2007-08-02 | Mount Sinai School Of Medicine | Methods and compositions for modulating the mobilization of stem cells |
| EP1991666A4 (en) | 2006-02-27 | 2009-06-10 | Moraga Biotech Corp | NON-EMBRYONIC TOTIPOTENT STEM CELLS OF BLASTOMERIC TYPE AND METHODS |
| AU2007264043B2 (en) | 2006-06-27 | 2012-03-15 | Nutratec S.R.L. | Extracts of Aphanizomenon Flos Aquae and nutritional, cosmetic and pharmaceutical compositions containing the same |
| EP1894941A1 (en) * | 2006-09-01 | 2008-03-05 | Institut Pasteur | Treatment of cervical carcinoma with a recombinant adenylate cyclase carrying HPV antigens |
| US8759090B2 (en) * | 2006-10-30 | 2014-06-24 | University Of Central Florida Research Foundation, Inc. | Stem cell banking system |
| US20090104160A1 (en) | 2007-02-01 | 2009-04-23 | Moraga Biotechnology Corporation | Mobilization of Stem Cells After Trauma and Methods Therefor |
| US20090053182A1 (en) | 2007-05-25 | 2009-02-26 | Medistem Laboratories, Inc. | Endometrial stem cells and methods of making and using same |
| ES2694018T3 (es) | 2007-07-02 | 2018-12-17 | Oncomed Pharmaceuticals, Inc. | Composiciones y métodos para el tratamiento y el diagnóstico del cáncer |
| CA2693144A1 (en) | 2007-07-17 | 2009-01-22 | The General Hospital Corporation | Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof |
| CN101978046A (zh) | 2007-10-30 | 2011-02-16 | 路易斯维尔大学研究基金会有限公司 | 非常小的胚胎样(vsel)干细胞的应用和分离 |
| CA2692634C (en) | 2007-11-09 | 2014-05-27 | Rnl Bio Co., Ltd | Method for isolating and culturing adult stem cells derived from human amniotic epithelium |
| GB2467982A (en) | 2008-05-08 | 2010-08-25 | Coretherapix Slu | Pluripotent adult stem cells |
| CN102333861A (zh) | 2008-09-30 | 2012-01-25 | 路易斯维尔大学研究基金会有限公司 | 用于分离非常小的胚胎样(vsel)干细胞的方法 |
| WO2010056341A2 (en) | 2008-11-12 | 2010-05-20 | The University Of Vermont And State Agriculture College | Compositions and methods for tissue repair |
| CN102333863A (zh) | 2009-01-13 | 2012-01-25 | 干细胞生物科技公司 | 非胚胎干细胞及其用途 |
| EP2412800A1 (en) | 2010-07-29 | 2012-02-01 | Koninklijke Nederlandse Akademie van Wetenschappen | Liver organoid, uses thereof and culture method for obtaining them |
| US8642339B2 (en) | 2009-02-03 | 2014-02-04 | Koninklijke Nederlandse Akademie Van Wetenschappen | Culture medium for epithelial stem cells and organoids comprising the stem cells |
| US8563307B2 (en) | 2009-02-24 | 2013-10-22 | James Wang | Treatment of immunosuppression-related disorders |
| WO2011119738A2 (en) | 2010-03-23 | 2011-09-29 | The Johns Hopkins University | Methods of treatment using stem cell mobilizers |
| CA2835313A1 (en) | 2010-05-07 | 2011-11-10 | Institut De Recherches Cliniques De Montreal | Gfi1b modulation and uses thereof |
| TWI686202B (zh) | 2010-08-04 | 2020-03-01 | 幹細胞生物科技公司 | 體幹細胞 |
| US8679474B2 (en) | 2010-08-04 | 2014-03-25 | StemBios Technologies, Inc. | Somatic stem cells |
| CN102008650B (zh) | 2010-12-16 | 2017-02-15 | 天津市医药科学研究所 | 一种治疗肿瘤的复方中药制剂及其制备方法 |
| TWI614340B (zh) | 2011-09-28 | 2018-02-11 | 幹細胞生物科技股份有限公司 | 體幹細胞及其製備方法 |
| CN104822827B (zh) | 2012-12-06 | 2020-01-21 | 干细胞生物科技公司 | Lgr5+体干细胞 |
| JP6581758B2 (ja) | 2013-06-24 | 2019-09-25 | ステムバイオス テクノロジーズ，インコーポレイテッド | 幹細胞及びそのデータを獲得する方法 |
| CN105687245A (zh) | 2014-12-13 | 2016-06-22 | 干细胞生物科技公司 | 制备注射液的方法 |
-
2009
- 2009-02-24 US US12/391,581 patent/US8563307B2/en active Active
-
2010
- 2010-01-29 TW TW099102621A patent/TWI496888B/zh not_active IP Right Cessation
- 2010-02-19 CN CN201080008875.6A patent/CN102325537B/zh not_active Expired - Fee Related
- 2010-02-19 ES ES10746666.6T patent/ES2582582T3/es active Active
- 2010-02-19 EP EP10746666.6A patent/EP2400971B1/en not_active Not-in-force
- 2010-02-19 JP JP2011551250A patent/JP5809068B2/ja not_active Expired - Fee Related
- 2010-02-19 WO PCT/US2010/024735 patent/WO2010099044A2/en not_active Ceased
-
2013
- 2013-10-04 US US14/045,950 patent/US9770473B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2400971A4 (en) | 2013-03-27 |
| ES2582582T3 (es) | 2016-09-13 |
| CN102325537A (zh) | 2012-01-18 |
| JP2012518646A (ja) | 2012-08-16 |
| EP2400971A1 (en) | 2012-01-04 |
| US20100215622A1 (en) | 2010-08-26 |
| WO2010099044A2 (en) | 2010-09-02 |
| CN102325537B (zh) | 2014-07-30 |
| US20140030237A1 (en) | 2014-01-30 |
| WO2010099044A9 (en) | 2010-12-16 |
| TW201040278A (en) | 2010-11-16 |
| EP2400971B1 (en) | 2016-05-18 |
| US8563307B2 (en) | 2013-10-22 |
| US9770473B2 (en) | 2017-09-26 |
| TWI496888B (zh) | 2015-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6871899B2 (ja) | 補助的免疫抑制処置を行わないｍａｐｃ療法 | |
| US9770473B2 (en) | Treatment of immunosuppression-related disorders | |
| TWI299752B (en) | Multipotent placental stem cell and methods thereof | |
| Sera et al. | Hematopoietic stem cell origin of adipocytes | |
| JP5432527B2 (ja) | 脳損傷及び疾患のｍａｐｃ治療 | |
| EP2539436B1 (en) | Modulation of macrophage activation | |
| JP2015159895A (ja) | 脳梗塞治療のための多能性幹細胞 | |
| CA2798895A1 (en) | Modulation of splenocytes in cell therapy | |
| US20060210544A1 (en) | Internally administered therapeutic agents for cranial nerve diseases comprising mesenchymal cells as an active ingredient | |
| CN105055450A (zh) | 人宫内膜干细胞在制备治疗卵巢早衰的药物中的应用 | |
| WO2023054317A1 (ja) | 放射線による神経障害の処置に用いる細胞調製物 | |
| WO2017199976A1 (ja) | 多能性幹細胞による周産期脳障害の改善及び治療 | |
| US20140004087A1 (en) | Endometrial regenerative cells for treatment of traumatic brain injury | |
| Serrato López et al. | The endometrium as a source of mesenchymal stem cells in domestic animals and possible applications in veterinary medicine | |
| MOHAMED et al. | The role of stem cells on the ovarian failure induced by busulfan in female albino rat | |
| AU2015202292B2 (en) | Modulation of macrophage activation | |
| JP2025523021A (ja) | 幹細胞由来エクソソームを含む抗癌組成物及びその製造方法 | |
| KR101590722B1 (ko) | 인간 혈액 유래 혈구 세포괴를 포함하는 신경계 질환 치료용 약학적 조성물 | |
| HK1175805B (en) | Modulation of macrophage activation | |
| HK1175805A (en) | Modulation of macrophage activation | |
| KR20140021156A (ko) | 인간 혈액 유래 혈구 세포괴를 포함하는 신경계 질환 치료용 약학적 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120104 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121010 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20121010 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131224 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140320 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140328 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140418 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140422 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150106 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150331 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150811 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150910 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5809068 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |